Boisen, Matthew L.
Uyigue, Eghosa
Aiyepada, John
Siddle, Katherine J.
Oestereich, Lisa
Nelson, Diana K. S.
Bush, Duane J.
Rowland, Megan M.
Heinrich, Megan L.
Eromon, Philomena
Kayode, Adeyemi T.
Odia, Ikponmwosa
Adomeh, Donatus I.
Muoebonam, Ekene B.
Akhilomen, Patience
Okonofua, Grace
Osiemi, Blessing
Omoregie, Omigie
Airende, Michael
Agbukor, Jacqueline
Ehikhametalor, Solomon
Aire, Chris Okafi
Duraffour, Sophie
Pahlmann, Meike
Böhm, Wiebke
Barnes, Kayla G.
Mehta, Samar
Momoh, Mambu
Sandi, John Demby
Goba, Augustine
Folarin, Onikepe A.
Ogbaini-Emovan, Ephraim
Asogun, Danny A.
Tobin, Ekaete A.
Akpede, George O.
Okogbenin, Sylvanus A.
Okokhere, Peter O.
Grant, Donald S.
Schieffelin, John S.
Sabeti, Pardis C.
Günther, Stephan
Happi, Christian T.
Branco, Luis M.
Garry, Robert F.
Article History
Received: 2 March 2020
Accepted: 8 May 2020
First Online: 26 May 2020
Competing interests
: MLB, DSG, JSS, PCS, CTH, LMB and RFG Are members of the The Viral Hemorrhagic Fever Consortium (ExternalRef removed). The VHFC is a partnership of academic and industry scientists who are developing diagnostic tests, therapeutic agents, and vaccines for Lassa fever, Ebola, and other severe diseases. Tulane University and its various academic and industry partners have filed US and foreign patent applications on behalf of the consortium for several of these technologies. Technical information may also be kept as trade secrets. If commercial products are developed, consortium members may receive royalties or profits. This does not alter our adherence to all policies of the NIH and <i>Scientific Reports</i> on sharing data and materials. Financial and non-financial competing interests that the editors consider relevant to the content of the manuscript have been disclosed. RFG and LMB are co-founders of Zalgen. DSKN, DJB, MMR, MLH are are Zalgen employees. PCS is a co-founder of Sherlock Biosciences. All other authors declare no competing interests.